BioSpace News Archive

SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on July 19 that the US FDA had granted an orphan drug designation for small cell lung cancer for SNB-101 (API: SN-38), a new polymer nanoparticle drug under development.

Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the second quarter 2023 after market close on Tuesday, August 8th, 2023.

Jacobio Pharma, a clinical-stage oncology company focusing on undruggable targets, is pleased to announce that the company will present its clinical results in the form of Proffered Paper presentation at the 2023 European Society for Medical Oncology Congress.

Cidara Therapeutics, Inc. (Nasdaq: CDTX) today provided an update on the status of its ongoing CD388 program for prevention of influenza A and B, which is the subject of an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has approved CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs.

Daiichi Sankyo (TSE: 4568) today announced that VANFLYTA® (quizartinib) has been approved by the U.S. Food and Drug Administration (FDA) in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD positive as detected by an FDA-approved test.

For the third straight quarter, San Francisco Health Plan (SFHP) is ranked number one among managed care plans for Medi-Cal COVID-19 vaccination rates.

ImmunityBio, Inc., a clinical-stage immunotherapy company, announced that it has executed financing to provide further working capital and support its ongoing business operations.

BBI-001 was well tolerated with no dose limiting toxicities. Single-dose administration demonstrated a statistically significant reduction of dietary iron absorption.

Genentech, a member of the Roche Group, announced that data from its ophthalmology portfolio will be highlighted in 25 abstracts at the 2023 American Society of Retina Specialists Annual Meeting, which will be held from July 28 to August 1 in Seattle, WA.